Defamation, Director of Medical Devices Company Reported

Pencemaran Nama Baik

Defamation of Good Name

Jakarta, CNN Indonesia -- The director of a company engaged in the health sector, PT Taishan Alkes Indonesia, reported a director of a foreign company to Polda Metro Jaya on Monday (30/8).

Reports related to allegations of defamation. The reported person in this case is the President Director of Hangzhou Clongene Biotech Co. Ltd with the initials ZS. Meanwhile, the reporting party is the director of PT Taishan Alkes Indonesia, Eiko Sihombing.

The complainant's attorney, Ardy Susanto, said that this report was made because the reported company posted a notification in the mass media that it was no longer collaborating with PT Taishan Alkes Indonesia.

“They said we have no cooperation, no license and so on. Yes, please prove that claim in court, don't spread it in public without being accountable," said Ardy at the Polda Metro Jaya, Monday (30/8).

According to Ardy, the impact of the notification made his client company and the local company that he supervises suffer losses. Because, said Ardy, the notification has tarnished the good name of his client's company.

"We feel defamed as if we are copying or hijacking their rights," he said.

Ardy hopes that this report can show that Indonesia has laws that must be obeyed, including by foreign companies.

"We want to remind that the Republic of Indonesia has laws. Not a single foreign company can act as it pleases without regard to the laws in Indonesia," said Ardy.

This report was received by the police with the number LP/B/4230/VIII/2021/SPKT/POLDA METRO JAYA dated August 30, 2021. The articles reported were Article 317 and/or Article 310 and/or Article 311 of the Criminal Code.

In the official website of Hangzhou Clongene Biotech Co. Ltd., they uploaded a notification letter regarding the termination of cooperation with PT Taishan Alkes Indonesia.

The letter explained that the cooperation was terminated because PT Taishan Alkes Indonesia used the product name 'Clungene' without their consent.

Not only that, PT Taishan Alkes Indonesia also applied for a distribution permit for overseas medical devices for rapid test products under the Clungene IND and TAISHAN INDONESIA brands in Indonesia.

In addition, it also produces products under that brand and states that these products are of the same quality as Clungene products from Hangzhou Clongene Biotech Co. Ltd.

“Our company never allowed PT. Taishan Alkes Indonesia to manufacture and sell products under the Clungene IND and Taishan Indonesia brands, and our company has never participated in the production and quality management of PT. Taishan Alkes Indonesia," stated in the letter.

Still in the letter, it was stated that all cooperative relations with PT Taishan Alkes Indonesia had ended. This includes a distribution agreement signed on August 1, 2020 and a cooperation agreement on October 5, 2020.

"Our company reserves the right to claim all liability and apply for compensation for violations from PT Taishan Alkes Indonesia," stated in the letter.

This news is taken from

Piagam Komite Audit

Audit Committee Charter

Jakarta - In connection with the company's IPO process and in order to comply with the provisions of article 12 paragraph 3 POJK 55/2015, then...